The EPS beat is modest and the company remains pre-revenue, so the stock move will hinge on ASCO 2026 data (May 30) and enrollment updates for APR-1051. The $30M financing removes near-term dilution risk but the stock is micro-cap with limited liquidity — watch for volatility around the ASCO presentation.
Price Chart
Executive Summary
Aprea Therapeutics reported Q1 2026 EPS of -$0.22 (GAAP), beating the -$0.23 consensus by 4.3%, but the headline EPS miss vs the -$0.32 consensus in the synthetic context is misleading — the actual GAAP EPS of -$0.22 is a beat. The company highlighted two partial responses in its WEE1 inhibitor trial and closed a $30M private placement, extending cash runway into Q1 2028. However, revenue was zero (no grant revenue), and the operating loss narrowed to $3.4M from $4.1M a year ago, reflecting cost discipline.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP EPS -$0.22 vs consensus -$0.23 (beat by 4.3%)
- No revenue reported (grant revenue was $0 vs $162K in Q1 2025)
- Operating loss narrowed to $3.4M from $4.1M in Q1 2025
- Cash and equivalents $46.5M as of March 31, 2026, up from $14.6M at year-end 2025
- Closed oversubscribed $30M private placement on March 31, 2026
- Two partial responses observed in Phase 1 WEE1 inhibitor trial (APR-1051)
- ASCO 2026 abstract accepted for APR-1051 data presentation on May 30, 2026
- Cash runway expected into Q1 2028
- ATRN-119 trial paused; exploring combination approaches
Financial Impact
EPS beat of ~4.3% on GAAP basis; cash position strengthened by $31.9M from $14.6M to $46.5M; no revenue
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products
- Dependence on single lead candidate APR-1051; ATRN-119 program paused
- High cash burn rate despite cost reductions
- Micro-cap stock with low liquidity and high volatility
- Clinical trial risks — early efficacy signals may not replicate in larger studies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293807 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 8w ago | 8-K | $0.8386 | awaiting T+60 | — | $0.5180 (−38.23%) |
Aug 12, 2026 10w ago | 8-K | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
Aug 12, 2026 10w ago | Press Release | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
May 13, 2026 23w ago | 8-K | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
May 13, 2026 23w ago | Press Release | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
Apr 30, 2026 25w ago | DEFA14A | $0.8000 $0.6247 | ▲ +21.91% | ▲ +25.02% | $0.5180 (+35.25%) |
Apr 22, 2026 26w ago | S-3 | $0.8840 $0.6690 | ▲ +24.32% | ▲ +29.34% | $0.5180 (+41.40%) |
Apr 21, 2026 26w ago | Press Release | $0.9070 $0.6900 | ▼ −23.93% | ▼ −30.82% | $0.5180 (−42.89%) |
Mar 31, 2026 29w ago | Insider Cluster | $0.7630 $0.7900 | ▲ +3.54% | ▼ −8.84% | $0.5180 (−32.11%) |
Mar 20, 2026 31w ago | EFFECT | $0.7620 $0.6990 | ▼ −8.27% | ▼ −22.69% | $0.5180 (−32.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers